Compugen Ltd. Stock Deutsche Boerse AG
Stocks
CW9
IL0010852080
Biotechnology & Medical Research
| Market Cap | 189M 170M 159M 144M 270M 18.03B 272M 1.91B 745M 9.36B 711M 696M 30.09B | P/E 2026 * |
-7.14x | P/E 2027 * | -7.25x |
|---|---|---|---|---|---|
| Enterprise Value | 189M 170M 159M 144M 270M 18.03B 272M 1.91B 745M 9.36B 711M 696M 30.09B | EV / Sales 2026 * |
20.5x | EV / Sales 2027 * | 24.4x |
| Free-Float |
99.78% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Compugen Ltd.
| 1 day | -2.88% |
| Manager | Title | Age | Since |
|---|---|---|---|
Eran Ophir
CEO | Chief Executive Officer | - | 23/09/2025 |
David Silberman
DFI | Director of Finance/CFO | 42 | 15/08/2024 |
Pierre Ferre
COO | Chief Operating Officer | 49 | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Anat Cohen-Dayag
CHM | Chairman | 59 | 23/09/2025 |
Gilead Halevy
BRD | Director/Board Member | 59 | 11/06/2018 |
Sanford Zweifach
BRD | Director/Board Member | 70 | 11/06/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.88% | -9.82% | - | - | 189M | |
| -2.01% | -7.86% | +60.74% | +70.97% | 68.92B | |
| +0.75% | +6.49% | +7.10% | +59.87% | 51.9B | |
| +3.72% | +7.81% | +13.15% | +42.55% | 48.73B | |
| +0.51% | +1.51% | +27.96% | +31.43% | 43.13B | |
| +2.70% | -3.66% | +307.41% | +547.01% | 41.48B | |
| +0.69% | -3.44% | +9.52% | +96.59% | 39.96B | |
| +0.06% | -2.02% | +11.25% | +43.27% | 30.6B | |
| -2.21% | -10.09% | +35.34% | -0.73% | 26.01B | |
| -0.39% | -6.92% | -13.60% | -14.40% | 22.27B | |
| Average | +0.09% | -4.58% | +50.98% | +97.39% | 41.44B | |
| Weighted average by Cap. | +0.47% | -4.28% | +54.94% | +104.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.24M 8.31M 7.75M 7.03M 13.19M 879M 13.27M 93.03M 36.33M 456M 34.69M 33.94M 1.47B | 7.75M 6.97M 6.5M 5.89M 11.06M 738M 11.13M 78.04M 30.47M 383M 29.1M 28.47M 1.23B |
| Net income | -26.46M -23.79M -22.21M -20.13M -37.78M -2.52B -38.02M -266M -104M -1.31B -99.36M -97.21M -4.2B | -26.95M -24.23M -22.61M -20.49M -38.48M -2.56B -38.72M -271M -106M -1.33B -101M -98.99M -4.28B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
